Biohaven Pharmaceutical Holding Company Ltd.
http://biohavenpharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Biohaven Pharmaceutical Holding Company Ltd.
Finance Watch: Investors Support Strategic Shifts At Cullinan, Cidara
Public Company Edition: Cullinan and Cidara shifted their strategic directions and found investors to bring along for the ride. Also, Intra-Cellular closed a post-Phase III $575m follow-on offering and Tarsus accessed up to $200m from Pharmakon.
Stock Watch: Risk And The Pharmaceutical Discount Rate
In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.
Senators Pressure US FDA To Issue New Guidance On Social Media Drug Promotion
Senators ask the agency to address the “regulatory loophole” permitting telehealth companies to promote prescription drugs without disclosing side effects and question if FDA has enforcement authority over third-party social media influencer promotions.
Orphan Drugs Dominate Latest EU Filings
Sotatercept, marstacimab, elafibranor, eplontersen, mirvetuximab soravtansine, troriluzole and tiratricol are among the latest products that the European Medicines Agency has started reviewing for potential EU marketing approval.
Company Information
- Industry
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Large Molecule
- Other Names / Subsidiaries
-
- Biohaven Pharmaceuticals, Inc.
- Biohaven Therapeutics Ltd.
- BioShin
- Kleo Pharmaceuticals Inc.
- Portage Biotech Inc.
- Portage Glasgow Limited (PGL)
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice